Influence of family history on risk of second primary cancers and survival in patients with squamous cell skin cancer.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
09 2020
Historique:
accepted: 14 12 2019
pubmed: 20 12 2019
medline: 15 5 2021
entrez: 20 12 2019
Statut: ppublish

Résumé

Patients with squamous cell skin cancer (SCC) have an excellent prognosis but second primary cancers (SPCs) weaken survival prospects. Family history is a known risk factor for cancer but whether it is a risk factor for SPC in patients with SCC is not known. To quantify the risk of family history on SPCs in patients with SCC and estimate survival probabilities of patients with SPCs depending on family history. With 13 945 histologically verified SCCs, relative risks (RRs) were estimated for family history using a generalized regression model. For survival analysis, hazard ratios (HRs) were assessed using a multivariable Cox proportional-hazards model. Family history of invasive SCC increased risk of second invasive SCC [RR = 42·92, 95% confidence interval (CI) 33·69-50·32] compared with risk without family history (RR 19·12, 95% CI 17·88-21·08). Family history of any nonskin cancer in invasive SCC increased risk of the same cancers to be diagnosed as SPC (RRF Family history of nonskin cancer was associated with approximately a doubling of risk for SPCs in patients with SCC. SPC increases the death rate in patients with SCC 3-4 times, irrespective of family history. Taking family history into account at SCC diagnosis may help prevention or early detection of SPCs. What's already known about this topic? Second primary cancers (SPCs) are frequently diagnosed in patients with invasive and in situ squamous cell carcinoma (SCC); some epidemiological studies suggest a link to immune dysfunction. Family history of cancer is a risk factor for practically all first primary cancers but whether it also influences risk of SPCs in patients with SCC is not known. The possible influence of family history on survival in patients with SCC remains to be established. Linked Comment: Youlden and Baade. Br J Dermatol 2020; 183:414-415.

Sections du résumé

BACKGROUND
Patients with squamous cell skin cancer (SCC) have an excellent prognosis but second primary cancers (SPCs) weaken survival prospects. Family history is a known risk factor for cancer but whether it is a risk factor for SPC in patients with SCC is not known.
OBJECTIVES
To quantify the risk of family history on SPCs in patients with SCC and estimate survival probabilities of patients with SPCs depending on family history.
METHODS
With 13 945 histologically verified SCCs, relative risks (RRs) were estimated for family history using a generalized regression model. For survival analysis, hazard ratios (HRs) were assessed using a multivariable Cox proportional-hazards model.
RESULTS
Family history of invasive SCC increased risk of second invasive SCC [RR = 42·92, 95% confidence interval (CI) 33·69-50·32] compared with risk without family history (RR 19·12, 95% CI 17·88-21·08). Family history of any nonskin cancer in invasive SCC increased risk of the same cancers to be diagnosed as SPC (RRF
CONCLUSIONS
Family history of nonskin cancer was associated with approximately a doubling of risk for SPCs in patients with SCC. SPC increases the death rate in patients with SCC 3-4 times, irrespective of family history. Taking family history into account at SCC diagnosis may help prevention or early detection of SPCs. What's already known about this topic? Second primary cancers (SPCs) are frequently diagnosed in patients with invasive and in situ squamous cell carcinoma (SCC); some epidemiological studies suggest a link to immune dysfunction. Family history of cancer is a risk factor for practically all first primary cancers but whether it also influences risk of SPCs in patients with SCC is not known. The possible influence of family history on survival in patients with SCC remains to be established. Linked Comment: Youlden and Baade. Br J Dermatol 2020; 183:414-415.

Identifiants

pubmed: 31853941
doi: 10.1111/bjd.18809
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

488-494

Subventions

Organisme : Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Pays : International
Organisme : Helsingin ja Uudenmaan Sairaanhoitopiiri
Pays : International
Organisme : Jane ja Aatos Erkon Säätiö
Pays : International
Organisme : Deutsche Krebshilfe
Pays : International
Organisme : Helsingin Yliopiston Tiedesäätiö
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Références

Hussain SK, Sundquist J, Hemminki K. Incidence trends of squamous cell and rare skin cancers in the Swedish national cancer registry point to calendar year and age-dependent increases. J Invest Dermatol 2010; 130:1323-8.
Rees JR, Zens MS, Gui J et al. Non melanoma skin cancer and subsequent cancer risk. PLOS ONE 2014; 9:e99674.
Green AC, Olsen CM. Cutaneous squamous cell carcinoma: an epidemiological review. Br J Dermatol 2017; 177:373-81.
Eisemann N, Jansen L, Castro FA et al. Survival with nonmelanoma skin cancer in Germany. Br J Dermatol 2016; 174:778-85.
Hemminki K, Zhang H, Czene K. Time trends and familial risks in squamous cell carcinoma of the skin. Arch Dermatol 2003; 139:885-9.
Hussain SK, Sundquist J, Hemminki K. The effect of having an affected parent or sibling on invasive and in situ skin cancer risk in Sweden. J Invest Dermatol 2009; 129:2142-7.
Frank C, Fallah M, Ji J et al. The population impact of familial cancer, a major cause of cancer. Int J Cancer 2014; 134:1899-906.
Hemminki K, Zhang H, Czene K. Familial invasive and in situ squamous cell carcinoma of the skin. Br J Cancer 2003; 88:1375-80.
Kharazmi E, Fallah M, Sundquist K, Hemminki K. Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ 2012; 345:e8076.
Hemminki K, Sundquist J, Brandt A. Do discordant cancers share familial susceptibility? Eur J Cancer 2012; 48:1200-7.
Frank C, Sundquist J, Yu H et al. Concordant and discordant familial cancer: familial risks, proportions and population impact. Int J Cancer 2017; 140:1510-16.
Rahman N. Realizing the promise of cancer predisposition genes. Nature 2014; 505:302-8.
Chahal HS, Lin Y, Ransohoff KJ et al. Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma. Nat Comm 2016; 7:12048.
Siiskonen SJ, Zhang M, Li WQ et al. A genome-wide association study of cutaneous squamous cell carcinoma among European descendants. Cancer Epidemiol Biomarkers Prev 2016; 25:714-20.
Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2010; 19:1686-95.
Hemminki K, Dong C. Subsequent cancers after in situ and invasive squamous cell carcinoma of the skin. Arch Dermatol 2000; 136:647-51.
Sud A, Thomsen H, Sundquist K et al. Risk of second cancer in Hodgkin lymphoma survivors and the influence of family history. J Clin Oncol 2017; 35:1584-90.
Zheng G, Hemminki A, Försti A et al. Second primary cancer after female breast cancer: familial risks and cause of death. Cancer Med 2019; 8:400-7.
Zheng G, Chattopadhyay S, Försti A et al. Familial risks of second primary cancers and mortality in ovarian cancer patients. Clin Epidemiol 2018; 10:1457-66.
Chattopadhyay S, Yu H, Sud A et al. Multiple myeloma: family history and mortality in second primary cancers. Blood Cancer J 2018; 8:75.
Chattopadhyay S, Hemminki O, Försti A et al. Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer. Prostate Cancer Prostatic Dis 2019; 22:143-9.
Chattopadhyay S, Zheng G, Hemminki O et al. Prostate cancer survivors: risk and mortality in second primary cancers. Cancer Med 2018; 7:5752-9.
Hemminki K, Ji J, Brandt A et al. The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies. Int J Cancer 2010; 126:2259-67.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: www.r-project.org/ (last accessed 2 January 2020).
Chattopadhyay S, Hemminki A, Försti A et al. Familial risks and mortality in second primary cancers in melanoma. JNCI Cancer Spectrum 2019; 2:pky068.
Birkeland S, Storm H, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60:183-9.
Zur Hausen H. The search for infectious causes of human cancers: where and why. Virology 2009; 392:1-10.
Bottomley MJ, Thomson J, Harwood C, Leigh I. The role of the immune system in cutaneous squamous cell carcinoma. Int J Mol Sci 2019; 20:2009.
Hortlund M, Arroyo Mühr LS, Storm H et al. Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer 2017; 140:1091-101.

Auteurs

S Chattopadhyay (S)

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.

G Zheng (G)

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.

A Hemminki (A)

Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

A Försti (A)

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden.

K Sundquist (K)

Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden.
Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.
Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Japan.

J Sundquist (J)

Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden.
Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.
Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Japan.

K Hemminki (K)

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden.
Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH